Illumina, Inc. (ILMN)
USD 74.75
(4.89%)
USD 74.75
(4.89%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.21 Billion USD | -17.3% |
| 2022 | 1.46 Billion USD | 18.67% |
| 2021 | 1.23 Billion USD | 2648.89% |
| 2020 | 45 Million USD | 121.84% |
| 2019 | -206 Million USD | -124.15% |
| 2018 | 853 Million USD | 668.47% |
| 2017 | 111 Million USD | -79.34% |
| 2016 | 537.27 Million USD | 66.95% |
| 2015 | 321.8 Million USD | -50.86% |
| 2014 | 654.88 Million USD | 317.24% |
| 2013 | 156.95 Million USD | -61.57% |
| 2012 | 408.39 Million USD | -19.03% |
| 2011 | 504.39 Million USD | 704.94% |
| 2010 | 62.66 Million USD | -56.95% |
| 2009 | 145.56 Million USD | 99.48% |
| 2008 | 72.97 Million USD | -67.58% |
| 2007 | 225.07 Million USD | 687.31% |
| 2006 | -38.32 Million USD | 24.34% |
| 2005 | -50.65 Million USD | 7.55% |
| 2004 | -54.78 Million USD | -516.55% |
| 2003 | 13.15 Million USD | -45.78% |
| 2002 | 24.26 Million USD | 840.09% |
| 2001 | -3.27 Million USD | 97.15% |
| 2000 | -114.95 Million USD | -443.19% |
| 1999 | -21.16 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2 Billion USD | 71.32% |
| 2024 Q1 | 1.16 Billion USD | -3.79% |
| 2024 Q3 | 1.73 Billion USD | -9.8% |
| 2023 Q1 | 1.48 Billion USD | 1.43% |
| 2023 FY | 1.21 Billion USD | -17.3% |
| 2023 Q2 | 1.41 Billion USD | -5.24% |
| 2023 Q3 | 1.26 Billion USD | -10.7% |
| 2023 Q4 | 1.21 Billion USD | -3.65% |
| 2022 Q1 | 1.26 Billion USD | 2.18% |
| 2022 Q4 | 1.46 Billion USD | -1.41% |
| 2022 Q3 | 1.48 Billion USD | 14.45% |
| 2022 FY | 1.46 Billion USD | 18.67% |
| 2022 Q2 | 1.3 Billion USD | 2.93% |
| 2021 Q2 | -1.81 Billion USD | -12.68% |
| 2021 Q4 | 1.23 Billion USD | -11.07% |
| 2021 Q1 | -1.6 Billion USD | -3675.56% |
| 2021 FY | 1.23 Billion USD | 2648.89% |
| 2021 Q3 | 1.39 Billion USD | 176.72% |
| 2020 Q3 | 90 Million USD | 23.29% |
| 2020 Q1 | -144 Million USD | 30.1% |
| 2020 Q2 | 73 Million USD | 150.69% |
| 2020 Q4 | 45 Million USD | -50.0% |
| 2020 FY | 45 Million USD | 121.84% |
| 2019 FY | -206 Million USD | -124.15% |
| 2019 Q4 | -206 Million USD | -3042.86% |
| 2019 Q1 | 191 Million USD | -77.61% |
| 2019 Q2 | -125 Million USD | -165.45% |
| 2019 Q3 | 7 Million USD | 105.6% |
| 2018 Q3 | 643 Million USD | 2472.0% |
| 2018 Q1 | -209 Million USD | -288.29% |
| 2018 Q2 | 25 Million USD | 111.96% |
| 2018 FY | 853 Million USD | 668.47% |
| 2018 Q4 | 853 Million USD | 32.66% |
| 2017 FY | 111 Million USD | -79.34% |
| 2017 Q4 | 111 Million USD | 331.25% |
| 2017 Q3 | -48 Million USD | -160.76% |
| 2017 Q2 | 79 Million USD | -70.41% |
| 2017 Q1 | 267 Million USD | -50.3% |
| 2016 FY | 537.27 Million USD | 66.95% |
| 2016 Q1 | 267.73 Million USD | -16.8% |
| 2016 Q3 | 425.62 Million USD | 430.58% |
| 2016 Q2 | 80.21 Million USD | -70.04% |
| 2016 Q4 | 537.27 Million USD | 26.23% |
| 2015 Q2 | 712.21 Million USD | -7.22% |
| 2015 FY | 321.8 Million USD | -50.86% |
| 2015 Q3 | 558.57 Million USD | -21.57% |
| 2015 Q4 | 321.8 Million USD | -42.39% |
| 2015 Q1 | 767.66 Million USD | 17.22% |
| 2014 Q4 | 654.88 Million USD | 45.19% |
| 2014 Q2 | 595.74 Million USD | 80.8% |
| 2014 Q3 | 451.06 Million USD | -24.29% |
| 2014 FY | 654.88 Million USD | 317.24% |
| 2014 Q1 | 329.5 Million USD | 109.93% |
| 2013 FY | 156.95 Million USD | -61.57% |
| 2013 Q3 | 167.66 Million USD | 145.52% |
| 2013 Q2 | 68.28 Million USD | -83.65% |
| 2013 Q4 | 156.95 Million USD | -6.39% |
| 2013 Q1 | 417.65 Million USD | 2.27% |
| 2012 Q4 | 408.39 Million USD | -16.72% |
| 2012 FY | 408.39 Million USD | -19.03% |
| 2012 Q3 | 490.38 Million USD | -3.52% |
| 2012 Q1 | 555.77 Million USD | 10.19% |
| 2012 Q2 | 508.25 Million USD | -8.55% |
| 2011 Q3 | 569.02 Million USD | 6.0% |
| 2011 Q4 | 504.39 Million USD | -11.36% |
| 2011 FY | 504.39 Million USD | 704.94% |
| 2011 Q2 | 536.83 Million USD | 52.05% |
| 2011 Q1 | 353.06 Million USD | 463.44% |
| 2010 Q1 | 82.17 Million USD | -43.55% |
| 2010 Q4 | 62.66 Million USD | -34.27% |
| 2010 FY | 62.66 Million USD | -56.95% |
| 2010 Q3 | 95.33 Million USD | 50.1% |
| 2010 Q2 | 63.51 Million USD | -22.71% |
| 2009 Q1 | -76.35 Million USD | -204.63% |
| 2009 Q2 | -72.39 Million USD | 5.19% |
| 2009 Q3 | 46.18 Million USD | 163.79% |
| 2009 Q4 | 145.56 Million USD | 215.22% |
| 2009 FY | 145.56 Million USD | 99.48% |
| 2008 Q2 | 281.91 Million USD | 0.19% |
| 2008 Q1 | 281.39 Million USD | 25.02% |
| 2008 FY | 72.97 Million USD | -67.58% |
| 2008 Q4 | 72.97 Million USD | 60.85% |
| 2008 Q3 | 45.36 Million USD | -83.91% |
| 2007 Q4 | 225.07 Million USD | -33.0% |
| 2007 Q3 | 335.91 Million USD | 5.33% |
| 2007 Q2 | 318.92 Million USD | 15.33% |
| 2007 Q1 | 276.54 Million USD | 821.61% |
| 2007 FY | 225.07 Million USD | 687.31% |
| 2006 FY | -38.32 Million USD | 24.34% |
| 2006 Q4 | -38.32 Million USD | 13.04% |
| 2006 Q3 | -44.07 Million USD | 71.03% |
| 2006 Q2 | -152.13 Million USD | -211.11% |
| 2006 Q1 | -48.9 Million USD | 3.45% |
| 2005 FY | -50.65 Million USD | 7.55% |
| 2005 Q3 | -50.17 Million USD | 8.05% |
| 2005 Q1 | -52.95 Million USD | 3.35% |
| 2005 Q2 | -54.56 Million USD | -3.05% |
| 2005 Q4 | -50.65 Million USD | -0.95% |
| 2004 Q1 | 16.69 Million USD | 26.93% |
| 2004 FY | -54.78 Million USD | -516.55% |
| 2004 Q4 | -54.78 Million USD | -0.86% |
| 2004 Q3 | -54.32 Million USD | -87.77% |
| 2004 Q2 | -28.93 Million USD | -273.29% |
| 2003 Q4 | 13.15 Million USD | -16.75% |
| 2003 FY | 13.15 Million USD | -45.78% |
| 2003 Q1 | 21.08 Million USD | -13.08% |
| 2003 Q2 | 19.49 Million USD | -7.56% |
| 2003 Q3 | 15.8 Million USD | -18.94% |
| 2002 FY | 24.26 Million USD | 840.09% |
| 2002 Q1 | 15.82 Million USD | 582.82% |
| 2002 Q2 | 25.47 Million USD | 60.93% |
| 2002 Q4 | 24.26 Million USD | -2.67% |
| 2002 Q3 | 24.92 Million USD | -2.14% |
| 2001 Q1 | -112.51 Million USD | 2.12% |
| 2001 Q3 | -2.78 Million USD | 73.19% |
| 2001 FY | -3.27 Million USD | 97.15% |
| 2001 Q4 | -3.27 Million USD | -17.56% |
| 2001 Q2 | -10.4 Million USD | 90.75% |
| 2000 Q1 | -15.06 Million USD | 0.0% |
| 2000 Q4 | -114.95 Million USD | 4.5% |
| 2000 FY | -114.95 Million USD | -443.19% |
| 2000 Q3 | -120.37 Million USD | -556.74% |
| 2000 Q2 | -18.32 Million USD | -21.65% |
| 1999 FY | -21.16 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 3177.157% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 20627.423% |
| Aspira Women's Health Inc. | -331 Thousand USD | 366867.372% |
| Biodesix, Inc. | 34.3 Million USD | -3438.636% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 21045.693% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 97772.357% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 97772.357% |
| Bionano Genomics, Inc. | 34.88 Million USD | -3380.305% |
| CareDx, Inc | -47.97 Million USD | 2630.432% |
| Check-Cap Ltd. | -24.75 Million USD | 5003.862% |
| Castle Biosciences, Inc. | -83.53 Million USD | 1553.353% |
| DarioHealth Corp. | -7.54 Million USD | 16183.731% |
| Exact Sciences Corporation | 1.94 Billion USD | 37.723% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 1570.339% |
| Guardant Health, Inc. | 220.22 Million USD | -451.249% |
| ICON Public Limited Company | 3.56 Billion USD | 65.901% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | -145.775% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 22446.336% |
| iSpecimen Inc. | -2.14 Million USD | 56632.903% |
| Standard BioTools Inc. | 46.5 Million USD | -2510.416% |
| MDxHealth SA | 18.88 Million USD | -6328.382% |
| 23andMe Holding Co. | -141.37 Million USD | 958.727% |
| Medpace Holdings, Inc. | -103.32 Million USD | 1274.911% |
| Myriad Genetics, Inc. | 88.1 Million USD | -1277.98% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -346900.9% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 49864.214% |
| NeoGenomics, Inc. | 269.19 Million USD | -350.981% |
| Neogen Corporation | 735.62 Million USD | -65.029% |
| Inotiv, Inc. | 382.14 Million USD | -217.677% |
| Natera, Inc. | -200.1 Million USD | 706.691% |
| OpGen, Inc. | 11.89 Million USD | -10108.644% |
| OPKO Health, Inc. | 230.68 Million USD | -426.263% |
| Psychemedics Corporation | 334 Thousand USD | -363373.054% |
| Prenetics Global Limited | -43.33 Million USD | 2901.298% |
| Prenetics Global Limited | -43.33 Million USD | 2901.298% |
| Precipio, Inc. | -386 Thousand USD | 314607.772% |
| Personalis, Inc. | -8.02 Million USD | 15233.383% |
| RadNet, Inc. | 1.14 Billion USD | -5.698% |
| Sera Prognostics, Inc. | -2.02 Million USD | 60139.565% |
| Sotera Health Company | 2.02 Billion USD | 40.061% |
| Neuronetics, Inc. | 2.79 Million USD | -43303.647% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 8015.498% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 8015.498% |
| Trinity Biotech plc | 63.73 Million USD | -1804.732% |
| T2 Biosystems, Inc. | 33.8 Million USD | -3490.76% |
| Twist Bioscience Corporation | -192.4 Million USD | 730.974% |
| Exagen Inc. | -12.77 Million USD | 9605.168% |